ARB 1467

Drug Profile

ARB 1467

Alternative Names: ARB 1468; ARB-1467; TKM HBV

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference; Surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 12 Dec 2016 Updated pharmacodynamics and adverse event data from a phase II trial in Hepatitis B (Treatment-experienced) released by Arbutus
  • 29 Sep 2016 Interim pharmacodynamics data from a phase II trial in Hepatitis B (Treatment-experienced) released by Arbutus
  • 08 Aug 2016 Arbutus receives patent issuance for Lipid nanoparticle (LNP) delivery technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top